Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 10/20 | 0.57 |
| ▸ | MMP9 | P14780 | 9/20 | 0.57 |
| ▸ | MMP3 | P08254 | 2/20 | 0.57 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | SCN1A | P35498 | 1/20 | 0.41 |
| ▸ | SCN4A | P35499 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8265816 | 0.88 | MMP2 (0.54) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL4038795 | 0.88 | MMP9 (0.57) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL6446699 | 0.80 | MMP2 (0.66) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL7477539 | 0.76 | MMP2 (0.41) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL7472025 | 0.72 | MMP2 (0.47) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL542225 | 0.70 | TNKS (0.62) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL5924484 | 0.69 | MMP2 (0.59) | MMP2MMP9MMP3MMP8MMP13 | |
| Phenytoin SCHEMBL11376417 | 0.67 | CYP2C9 (0.88) | MMP2MMP9MMP3ALDH1A1CACNA1F | |
| SCHEMBL713351 | 0.66 | MMP9 (0.61) | MMP2MMP9MMP3MMP8MMP13 | |
| SCHEMBL3195931 | 0.64 | MMP9 (0.59) | MMP2MMP9MMP3MMP8MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080096897-A1 | 5-(1,1'Biphenyl)-4-Yl-5-(4-(4-Aminoacylphenyl)-Piperazin)-1-Yl-Pyrimidine-2,4,6,-Trione Derivatives, As Inhibitors Of Zinc Metallondopeptidases, Their Preparation And Use | UNIVERSITE DE LIEGE (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096897-A1 | 5-(1,1'Biphenyl)-4-Yl-5-(4-(4-Aminoacylphenyl)-Piperazin)-1-Yl-Pyrimidine-2,4,6,-Trione Derivatives, As Inhibitors Of Zinc Metallondopeptidases, Their Preparation And Use | UNIVERSITE DE LIEGE (BE) | 2008-04-24 | — | — | US | disclosed |
| US-20080096897-A1 | 5-(1,1'Biphenyl)-4-Yl-5-(4-(4-Aminoacylphenyl)-Piperazin)-1-Yl-Pyrimidine-2,4,6,-Trione Derivatives, As Inhibitors Of Zinc Metallondopeptidases, Their Preparation And Use | UNIVERSITE DE LIEGE (BE) | 2008-04-24 | — | — | US | disclosed |
| EP-1784397-A1 | 5-(1,1'-BIPHENYL)-4-YL-5-(4-(4-AMINOACYLPHENYL)-PIPERAZIN)-1-YL-PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, AS INHIBITORS OF ZINC METALLONDOPEPTIDASES, THEIR PREPARATION AND USE | Université de Liège (BE) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021533-A1 | 5-(1,1'-BIPHENYL)-4-YL-5-(4-(4-AMINOACYLPHENYL)-PIPERAZIN)-1-YL-PYRIMIDINE-2,4,6-TRIONE DERIVATIVES, AS INHIBITORS OF ZINC METALLONDOPEPTIDASES, THEIR PREPARATION AND USE | UNIVERSITE DE LIEGE (BE) | 2006-03-02 | — | — | WO | disclosed |
| US-6472396-B1 | Barbituric acid derivatives, processes for their production and pharmaceutical agents containing these compounds | ROCHE DIAGNOSTICS GMBH (DE) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096897-A1 | 5-(1,1'Biphenyl)-4-Yl-5-(4-(4-Aminoacylphenyl)-Piperazin)-1-Yl-Pyrimidine-2,4,6,-Trione Derivatives, As Inhibitors Of Zinc Metallondopeptidases, Their Preparation And Use | CTRL, TPP1, SERPINB1 | MMP2 16/4885MMP9 54/4885MMP3 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.